| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB) | PROVEAN (Chen et al. 2020) | OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10) | Accuracy (OncoKB benchmark (positive set not stated), default categorical calls) | 0.67 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB) | PROVEAN (Chen et al. 2020) | OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10) | Negative predictive value (OncoKB benchmark (positive set not stated), default categorical calls) | 0.8 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB) | PROVEAN (Chen et al. 2020) | OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10) | Precision (OncoKB benchmark (positive set not stated), default categorical calls) | 0.61 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB) | PROVEAN (Chen et al. 2020) | OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10) | Specificity (OncoKB benchmark (positive set not stated), default categorical calls) | 0.45 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB) | PROVEAN (Chen et al. 2020) | OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | Accuracy (OncoKB benchmark (positive set not stated), median-score threshold) | 0.69 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB) | PROVEAN (Chen et al. 2020) | OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | Negative predictive value (OncoKB benchmark (positive set not stated), median-score threshold) | 0.7 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB) | PROVEAN (Chen et al. 2020) | OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | Precision (OncoKB benchmark (positive set not stated), median-score threshold) | 0.69 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB) | PROVEAN (Chen et al. 2020) | OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | Recall (OncoKB benchmark (positive set not stated), median-score threshold) | 0.7 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB) | PROVEAN (Chen et al. 2020) | OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | Specificity (OncoKB benchmark (positive set not stated), median-score threshold) | 0.68 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability) | PROVEAN (Chen et al. 2020) | Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | Accuracy (cell viability drivers versus neutral, default categorical calls) | 0.62 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability) | PROVEAN (Chen et al. 2020) | Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | Negative predictive value (cell viability drivers versus neutral, default categorical calls) | 0.7 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability) | PROVEAN (Chen et al. 2020) | Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | Precision (cell viability drivers versus neutral, default categorical calls) | 0.57 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability) | PROVEAN (Chen et al. 2020) | Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | Recall (cell viability drivers versus neutral, default categorical calls) | 0.78 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability) | PROVEAN (Chen et al. 2020) | Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | Specificity (cell viability drivers versus neutral, default categorical calls) | 0.48 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability) | PROVEAN (Chen et al. 2020) | Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21) | Accuracy (cell viability drivers versus neutral, median-score threshold) | 0.59 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability) | PROVEAN (Chen et al. 2020) | Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21) | Negative predictive value (cell viability drivers versus neutral, median-score threshold) | 0.59 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability) | PROVEAN (Chen et al. 2020) | Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21) | Precision (cell viability drivers versus neutral, median-score threshold) | 0.58 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability) | PROVEAN (Chen et al. 2020) | Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21) | Specificity (cell viability drivers versus neutral, median-score threshold) | 0.58 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB) | SIFT (Chen et al. 2020) | OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10) | Accuracy (OncoKB benchmark (positive set not stated), default categorical calls) | 0.61 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB) | SIFT (Chen et al. 2020) | OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10) | Negative predictive value (OncoKB benchmark (positive set not stated), default categorical calls) | 0.75 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB) | SIFT (Chen et al. 2020) | OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10) | Precision (OncoKB benchmark (positive set not stated), default categorical calls) | 0.57 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB) | SIFT (Chen et al. 2020) | OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10) | Specificity (OncoKB benchmark (positive set not stated), default categorical calls) | 0.33 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB) | SIFT (Chen et al. 2020) | OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | Accuracy (OncoKB benchmark (positive set not stated), median-score threshold) | 0.61 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB) | SIFT (Chen et al. 2020) | OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | Negative predictive value (OncoKB benchmark (positive set not stated), median-score threshold) | 0.61 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB) | SIFT (Chen et al. 2020) | OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | Precision (OncoKB benchmark (positive set not stated), median-score threshold) | 0.6 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB) | SIFT (Chen et al. 2020) | OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | Recall (OncoKB benchmark (positive set not stated), median-score threshold) | 0.63 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB) | SIFT (Chen et al. 2020) | OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | Specificity (OncoKB benchmark (positive set not stated), median-score threshold) | 0.58 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability) | SIFT (Chen et al. 2020) | Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | Accuracy (cell viability drivers versus neutral, default categorical calls) | 0.56 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability) | SIFT (Chen et al. 2020) | Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | Negative predictive value (cell viability drivers versus neutral, default categorical calls) | 0.66 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability) | SIFT (Chen et al. 2020) | Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | Precision (cell viability drivers versus neutral, default categorical calls) | 0.53 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability) | SIFT (Chen et al. 2020) | Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | Recall (cell viability drivers versus neutral, default categorical calls) | 0.8 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability) | SIFT (Chen et al. 2020) | Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | Specificity (cell viability drivers versus neutral, default categorical calls) | 0.35 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability) | SIFT (Chen et al. 2020) | Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21) | Accuracy (cell viability drivers versus neutral, median-score threshold) | 0.56 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability) | SIFT (Chen et al. 2020) | Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21) | Negative predictive value (cell viability drivers versus neutral, median-score threshold) | 0.56 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability) | SIFT (Chen et al. 2020) | Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21) | Precision (cell viability drivers versus neutral, median-score threshold) | 0.55 |
|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability) | SIFT (Chen et al. 2020) | Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21) | Specificity (cell viability drivers versus neutral, median-score threshold) | 0.53 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | PROVEAN rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv) | Average precision (CGC missense, all genes) | 0.588 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | PROVEAN rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv) | AUROC (CGC missense, all genes) | 0.819 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | PROVEAN rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv) | Average precision (CGC missense, oncogenes (gain of function)) | 0.646 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | PROVEAN rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv) | AUROC (CGC missense, oncogenes (gain of function)) | 0.813 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | PROVEAN rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv) | Average precision (CGC missense, tumour suppressors (loss of function)) | 0.548 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | PROVEAN rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv) | AUROC (CGC missense, tumour suppressors (loss of function)) | 0.859 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | SIFT rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv) | Average precision (CGC missense, all genes) | 0.442 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | SIFT rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv) | AUROC (CGC missense, all genes) | 0.778 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | SIFT rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv) | Average precision (CGC missense, oncogenes (gain of function)) | 0.52 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | SIFT rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv) | AUROC (CGC missense, oncogenes (gain of function)) | 0.764 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | SIFT rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv) | Average precision (CGC missense, tumour suppressors (loss of function)) | 0.383 |
|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role) | SIFT rank score, dbNSFP 5.3.1a (Lee 2026) | CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv) | AUROC (CGC missense, tumour suppressors (loss of function)) | 0.817 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | PROVEAN (Livesey and Marsh 2025) | Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense | Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each) | 48.6 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | SIFT (Livesey and Marsh 2025) | Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense | Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each) | 34.8 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | PROVEAN (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets) | 48.1 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | PROVEAN (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets | Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets) | 5.47 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | SIFT (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets) | 39.3 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | SIFT (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets | Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets) | 1.22 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | PROVEAN (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only) | 51 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | SIFT (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only) | 39.9 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | PROVEAN (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only) | 46 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | SIFT (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only) | 38.8 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | PROVEAN (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score) | 50 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | SIFT (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score) | 41.8 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | PROVEAN (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only) | 48.3 |
|---|
| Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) | SIFT (Livesey and Marsh 2025) | Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only) | 40.3 |
|---|